Fu-Quan Liu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1297920/publications.pdf

Version: 2024-02-01

33	564	687363 13	677142 22
papers	citations	h-index	g-index

34	34	34	793
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Digestive and Liver Disease, 2018, 50, 323-330.	0.9	64
2	Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine, 2018, 36, 151-158.	6.1	64
3	Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome. Frontiers in Immunology, 2020, 11, 1149.	4.8	59
4	Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial. Scientific Reports, 2016, 6, 21011.	3.3	32
5	Transjugular intrahepatic portosystemic shunt for Buddâ€“Chiari syndrome with diffuse occlusion of hepatic veins. Scientific Reports, 2016, 6, 36380.	3.3	29
6	Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 301-307.	0.9	27
7	Tanshinone IIA Protects against Dextran Sulfate Sodium- (DSS-) Induced Colitis in Mice by Modulation of Neutrophil Infiltration and Activation. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	4.0	24
8	Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. CardioVascular and Interventional Radiology, 2017, 40, 1372-1382.	2.0	22
9	Cannabinoid Receptor 1/miR-30b-5p Axis Governs Macrophage NLRP3 Expression and Inflammasome Activation in Liver Inflammatory Disease. Molecular Therapy - Nucleic Acids, 2020, 20, 725-738.	5.1	22
10	Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World Journal of Gastroenterology, 2015, 21, 12439.	3.3	22
11	Neutrophil recruitment mediated by sphingosine 1-phosphate (S1P)/S1P receptors during chronic liver injury. Cellular Immunology, 2021, 359, 104243.	3.0	20
12	Techniques and long-term effects of transjugular intrahepatic portosystemic shunt on liver cirrhosis-related thrombotic total occlusion of main portal vein. Scientific Reports, 2017, 7, 10868.	3.3	17
13	Parallel transjugular intrahepatic portosystemic shunt for controlling portal hypertension complications in cirrhotic patients. World Journal of Gastroenterology, 2014, 20, 11835.	3.3	16
14	Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis: An analysis of data from CHESS-1601 trial. Journal of Hepatology, 2018, 68, 210-211.	3.7	13
15	Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus. World Journal of Gastrointestinal Oncology, 2018, 10, 496-504.	2.0	13
16	Iodine density Changes in Hepatic and Splenic Parenchyma in Liver Cirrhosis with Dual Energy CT (DECT): A Preliminary Study. Academic Radiology, 2019, 26, 872-877.	2.5	13
17	An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension. Cell Reports Medicine, 2022, 3, 100563.	6.5	13
18	Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome. World Journal of Gastroenterology, 2015, 21, 2413.	3.3	12

#	Article	IF	Citations
19	Techniques of TIPS in the treatment of liver cirrhosis combined with incompletely occlusive main portal vein thrombosis. Scientific Reports, 2016, 6, 33069.	3.3	11
20	Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol. World Journal of Gastroenterology, 2015, 21, 9544.	3.3	9
21	Practice guidance for the use of terlipressin for liver cirrhosisâ€“related complications. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210982.	3.2	8
22	Pathological Predictors of Shunt Stenosis and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt. BioMed Research International, 2016, 2016, 1-8.	1.9	7
23	Evaluation of mid- and long-term efficacy of shunt limiting for hepatic myelopathy after transjugular intrahepatic portosystemic shunt. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 440-446.	1.5	7
24	Pathological Features of Mitochondrial Ultrastructure Predict Susceptibility to Post-TIPS Hepatic Encephalopathy. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-9.	1.9	7
25	Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. World Journal of Gastroenterology, 2021, 27, 416-427.	3.3	6
26	Transjugular intrahepatic portosystemic shunt and splenectomy are more effective than endoscopic therapy for recurrent variceal bleeding in patients with idiopathic noncirrhotic portal hypertension. World Journal of Clinical Cases, 2020, 8, 1871-1877.	0.8	6
27	Dual Targeting of Angipoietinâ€1 and von Willebrand Factor by microRNAâ€671â€5p Attenuates Liver Angiogenesis and Fibrosis. Hepatology Communications, 2022, 6, 1425-1442.	4.3	6
28	Benefits of Early Treatment for Patients with Hepatic Myelopathy Secondary to TIPS: A Retrospective Study in Northern China. Scientific Reports, 2018, 8, 15184.	3.3	5
29	Silencing IQGAP1 alleviates hepatic fibrogenesis via blocking bone marrow mesenchymal stromal cell recruitment to fibrotic liver. Molecular Therapy - Nucleic Acids, 2022, 27, 471-483.	5.1	5
30	Hepatic parenchyma and vascular blood flow changes after TIPS with spectral CT iodine density in HBV-related liver cirrhosis. Scientific Reports, 2021, 11, 10535.	3.3	4
31	Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report. World Journal of Clinical Cases, 2019, 7, 3282-3288.	0.8	1
32	Association of hepatic vein Lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death. Journal of International Medical Research, 2017, 45, 1148-1157.	1.0	0
33	Correlation analysis of collagen proportionate area in Budd-Chiari syndrome: A preliminary clinicopathological study. World Journal of Clinical Cases, 2019, 7, 130-136.	0.8	0